These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26739488)

  • 41. Intestinal CART is a regulator of GIP and GLP-1 secretion and expression.
    Shcherbina L; Lindqvist A; Thorén Fischer AH; Ahlqvist E; Zhang E; Falkmer SE; Renström E; Koffert J; Honka H; Wierup N
    Mol Cell Endocrinol; 2018 Nov; 476():8-16. PubMed ID: 29627317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hydrogen Sulfide and Sulfate Prebiotic Stimulates the Secretion of GLP-1 and Improves Glycemia in Male Mice.
    Pichette J; Fynn-Sackey N; Gagnon J
    Endocrinology; 2017 Oct; 158(10):3416-3425. PubMed ID: 28977605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells.
    Handgraaf S; Dusaulcy R; Visentin F; Philippe J; Gosmain Y
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618657
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nateglinide stimulates glucagon-like peptide-1 release by human intestinal L cells via a K(ATP) channel-independent mechanism.
    Kitahara Y; Miura K; Yasuda R; Kawanabe H; Ogawa S; Eto Y
    Biol Pharm Bull; 2011; 34(5):671-6. PubMed ID: 21532155
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
    Ruetten H; Gebauer M; Raymond RH; Calle RA; Cobelli C; Ghosh A; Robertson RP; Shankar SS; Staten MA; Stefanovski D; Vella A; Wright K; Fryburg DA;
    Metab Syndr Relat Disord; 2018 Oct; 16(8):406-415. PubMed ID: 30117761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Curcumin improves glucose tolerance via stimulation of glucagon-like peptide-1 secretion.
    Kato M; Nishikawa S; Ikehata A; Dochi K; Tani T; Takahashi T; Imaizumi A; Tsuda T
    Mol Nutr Food Res; 2017 Mar; 61(3):. PubMed ID: 27990751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glucagon-like peptide-1 and islet lipolysis.
    Sörhede Winzell M; Ahrén B
    Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-molecular fraction of wheat protein hydrolysate stimulates glucagon-like peptide-1 secretion in an enteroendocrine L cell line and improves glucose tolerance in rats.
    Kato M; Nakanishi T; Tani T; Tsuda T
    Nutr Res; 2017 Jan; 37():37-45. PubMed ID: 28215313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats.
    Yu Y; Wang X; Liu C; Yao D; Hu M; Li J; Hu N; Liu L; Liu X
    Toxicol Appl Pharmacol; 2013 Feb; 266(3):375-84. PubMed ID: 23200776
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pancreatic-derived factor impaired glucagon-like Peptide-1 production from GLUTag enterendorine L-cell line and intestines.
    Lai F; Chen Y; Lin H; Wang X; Zhu X; Li Y; Xiao H; Cao X
    Mol Cell Endocrinol; 2017 Sep; 452():110-119. PubMed ID: 28549991
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. βHB inhibits glucose-induced GLP-1 secretion in GLUTag and human jejunal enteroids.
    Elebring E; Casselbrant A; Persson SMT; Fändriks L; Wallenius V
    J Mol Endocrinol; 2023 May; 70(4):. PubMed ID: 36810364
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glucagon-like peptide 1 (GLP-1) and metabolic diseases.
    Rotella CM; Pala L; Mannucci E
    J Endocrinol Invest; 2005 Sep; 28(8):746-58. PubMed ID: 16277173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. On the role of the gut in diabetic hyperglucagonaemia.
    Lund A
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction.
    Fujioka K
    JAAPA; 2007 Dec; Suppl():3-8. PubMed ID: 18217245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment.
    Rasouli M; Ahmad Z; Omar AR; Allaudin ZN
    BMC Biotechnol; 2011 Nov; 11():99. PubMed ID: 22047106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ghrelin Is a Novel Regulator of GLP-1 Secretion.
    Gagnon J; Baggio LL; Drucker DJ; Brubaker PL
    Diabetes; 2015 May; 64(5):1513-21. PubMed ID: 25412624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.